Who
William E. Rote
Chief Research Officer
Company insider
Files Form 4 as: Chief Research Officer, Travere Therapeutics.
In numbers
- Trades disclosed
- 142
- Buys
- 0
- Sells
- 48
- Bought
- $0
- Sold
- $32.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Feb 2017
- Last trade
- 16 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $4.1M65,104 at $63.12 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $3.0M47,746 at $63.61 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —350 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —55,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —57,500 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —350 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —55,000 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —57,500 at $0.00 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,286350 at $17.96 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $850K55,000 at $15.46 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.5M57,500 at $26.88 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,286350 at $17.96 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $850K55,000 at $15.46 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.5M57,500 at $26.88 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $4.1M65,104 at $63.12 | filing |
| 16 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Sold | $3.0M47,746 at $63.61 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $985K39,000 at $25.25 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,000 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —39,650 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TVTX Travere TherapeuticsBiotechnology | SEC FORM 4 Code M | $712K39,650 at $17.96 | filing |
News
No headline names them, or the companies they trade most, lately.